

• • • , • • •

, • •

(), ' , - , - ,

[1, 5, 8, 10].

20 – 30 % [13].

()
[7, 11, 12, 14],

[4].

, , : ;
[9].

[2].

(-)

(50,4 ± 1,71) 128

19 73 (,) (4)

(- , -8) « » ().

« », . : 1 30 ; - 32 ; - 33 2 2,5 % , 2 5 , 100 (.1) 3 20 -33 2 2,5 % 2 5 , 100 (.1) 3 20 . 25 3 . «Microsoft Excel».

25

, - . 3 ($< 0,05$) 25- 3 . ($< 0,01$), 1, 2. 25 -

1-

-	(n = 20)	25			3		
		(n = 30), (n = 33)	(n = 30), (n = 33)	(n = 26), (n = 30)			
-	24,2 ± 2,25	48,36 ± 2,67	35,57 ± 2,08	36,15 ± 2,24			
		49,93 ± 3,82	28,91 ± 2,18	26,23 ± 2,1			
-8	21,6 ± 1,72	38,87 ± 3,99	30,13 ± 2,64	31,73 ± 2,78			
		43,62 ± 4,04	27,3 ± 2,79	26,73 ± 3,0			
1.	-	()				
2.	-	()				
3.		($< 0,05$)					
4.		($< 0,05$)					

-8

25-

3

-8

, 2'2010

2-

-	(n = 20)	25		3
		(n = 32), (n = 33)	(n = 32), (n = 33)	(n = 28), (n = 30)
-	24,2 ± 2,25	<u>82,39 ± 4,94</u> 87,87 ± 5,41	<u>55,78 ± 4,40</u> 33,36 ± 2,78	<u>58,89 ± 4,64</u> 31,33 ± 2,16
-8	21,6 ± 1,72	<u>62,62 ± 5,24</u> 62,21 ± 4,59	<u>40,06 ± 4,34</u> 32,82 ± 2,8	<u>38,11 ± 4,25</u> 33,8 ± 2,98
1.	-	()	
2.	-	()	
3.		(< 0,05)		
4.		(< 0,05)		

, - , -8

25 (CD3) (3, 4)

CD3

(< 0,01).

CD3

(< 0,01),

(< 0,001),

CD3

(< 0,05).

25

3-

-	(n = 20)	25		3
		(n = 30), (n = 33)	(n = 30), (n = 33)	(n = 26), (n = 30)
CD3	55,4 ± 1,51	<u>46,7 ± 1,29</u> 46,5 ± 0,97	<u>35,1 ± 0,53</u> 40,9 ± 0,81	<u>35,3 ± 0,58</u> 40,4 ± 0,83
CD4	40,2 ± 1,34	<u>34,4 ± 0,48</u> 33,9 ± 0,48	<u>35,57 ± 2,08</u> 28,91 ± 2,18	<u>36,15 ± 2,24</u> 26,23 ± 2,12
CD8	25,4 ± 0,79	<u>24,0 ± 0,73</u> 24,9 ± 0,64	<u>24,5 ± 0,63</u> 26,9 ± 0,64	<u>24,6 ± 0,67</u> 27,1 ± 0,69
CD4/CD8	1,6 ± 0,09	<u>1,47 ± 0,06</u> 1,39 ± 0,05	<u>1,47 ± 0,05</u> 1,55 ± 0,06	<u>1,46 ± 0,05</u> 1,53 ± 0,06
1.	-	()	
2.	-	()	
3.		(< 0,05)		
4.		(< 0,05)		

-	(n = 20)			
		(n = 32), (n = 33)	25 (n = 32), (n = 33)	3 (n = 28), (n = 30)
CD3	55,4 ± 1,51	$\frac{38,5 \pm 1,2}{38,8 \pm 1,22}$	$\frac{43,5 \pm 0,97}{50,2 \pm 0,85}$	$\frac{43,4 \pm 1,02}{48,7 \pm 0,96}$
CD4	40,2 ± 1,34	$\frac{25,8 \pm 0,8}{25,6 \pm 0,67}$	$\frac{30,5 \pm 0,87}{37,6 \pm 0,93}$	$\frac{30,2 \pm 0,95}{36,9 \pm 0,95}$
CD8	25,4 ± 0,79	$\frac{22,3 \pm 0,56}{23,1 \pm 0,49}$	$\frac{22,6 \pm 0,51}{25,5 \pm 0,54}$	$\frac{22,5 \pm 0,58}{24,9 \pm 0,71}$
CD4/CD8	1,6 ± 0,09	$\frac{1,19 \pm 0,07}{1,13 \pm 0,04}$	$\frac{1,37 \pm 0,05}{1,49 \pm 0,04}$	$\frac{1,37 \pm 0,06}{1,51 \pm 0,05}$
1.	-	()	
2.	-	()	
3.		(< 0,05)		
4.		(< 0,05)		

(< 0,01) (< 0,001) CD4 (< 0,05). (< 0,05). (CD4/CD8) (< 0,001).

1.

2.

3.

SUMMARY

TIOTRASOLIN INFLUENCES CLINICAL AND IMMUNOLOGICAL INDICES AS A PART OF COMPLEX THERAPY IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE

Murenets N. A., Orlovsky V. F.

Medical Institute of Sumy State University, Sumy

Effect of Tiotriasolin on clinical and immunological indices was researched in patients with nonalcoholic fatty liver disease. No reliable clinical differences were found between patients with standart treatment and with Tiotriasolin as a part. Additional usage of Tiotriasolin leads to decrease proinflammatory cytokines levels, immunodeficient state were disappeared instead of standart therapy.

1. // – 2007. – 3. – С. 98–106. /
2. : // / – 2000. – . 9. – . 4. – . 30–36.
3. / : – 2002. – . 8. – . 64–70. //
4. : « » // – 2008. – 4 (42). – . 54–57.
5. – 2001. – 2. – . 12–15. / //
6. // – 2001. – 2. – . 15–18. / ,
7. / // – 2006. – 17. – . 2–5.
8. , // – 2005. – 3. – . 89–95.
9. – 2001. – 3. – . 18–25. / //
10. , / / – 2004. – 5 (19). – . 41–45.
11. Lam Brian. Treatment Options for Nonalcoholic Fatty Liver Disease / Brian Lam, Zobair M. Younossi // Ther. Adv. Gastroenterol. – 2010. – Vol. 13(2). – P. 121–137.
12. Comar K.M. Review Article: Drug Therapy for Non-Alcoholic Fatty Liver Disease /K.M. Comar, R.K. Sterling // Aliment Pharmacol Ther. – 2006. – Vol. 23(2). – P. 207–215.
13. Adams Leon A. Nonalcoholic fatty liver disease / Leon A. Adams, Paul Angulo, Keith D. Lindor // CMAJ. – 2005. – Vol. 172(7). – P. 899–905.
14. Lindor K.D. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial / K.D. Lindor, K.V. Kowdley, E.J. Heathcote et al. // Hepatology. – 2004. – Vol. 39. – P. 770–778.

6 2010 .